Quarterly financial reports aren't all that important for pre-revenue
biotechs, though they do give investors a chance to hear updated
commentary about clinical trials, development plans, and so on. There
were no blockbuster announcements from Neurocrine Biosciences (NASDAQ:NBIX)
this quarter, but the company now has a clear path to begin the pivotal
study of its most valuable 100%-owned asset. I would prefer to see/hear
more about the company's efforts to get another drug into clinical
development, but I continue to believe that Elagolix and NBI-98854
('854) support a fair value above $17 today with a vital clinical update
due late in the year or early next.
Read the full article here:
Neurocrine Biosciences Moving Ahead With '854
No comments:
Post a Comment